On July 10, 2026, Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program and related assets to Servier Pharmaceuticals LLC and Les Laboratoires Servier. The company received $1.55 billion in upfront cash and is eligible for up to $1.1 billion in additional regulatory and commercial milestone payments, for a total potential consideration of $2.65 billion. This filing provides pro forma financial information reflecting the transaction, including an estimated gain on sale of $1.487 billion before taxes. Following the divestiture, the company will focus on its cardiovascular pipeline, including EDG-7500, EDG-15400, and EDG-003. Edgewise Therapeutics is a biotechnology company that develops therapeutics for cardiovascular and muscular diseases.

Edgewise Therapeutics, Inc. completed the acquisition of its muscular dystrophy program, including the sevasemten compound and related assets, by Servier Pharmaceuticals LLC and Les Laboratoires Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, totaling a potential $2.65 billion. Edgewise Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for patients with muscular dystrophy and other rare diseases.